The Structure of Synthetic Oligosaccharides in Relation to Factor IXa Inhibition^[a]

Summary

We investigated the effect of various oligosaccharides (OS) on the inhibition of factor IXa by antithrombin (AT) in a purified system. The OS comprised the AT-binding pentasaccharide sequence prolonged by saccharide chains with various lengths and charges. We show that factor IXa inhibition depended on the molecular weight of the OS. Factor IXa was not inhibited by the AT-binding pentasaccharide alone, but was inhibited if it was prolonged by a sulphated dodecasaccharide at the non-reducing end. The overall charge was also important since factor IXa inhibition was negligible if the pentasaccharide was prolonged by a non-sulphated dodecasaccharide. Using compounds containing a non-sulphated spacer, we showed that the central part of the OS was not critical. This study therefore demonstrates that the minimal OS structure necessary for catalysing factor IXa inhibition by AT is close to that required for catalysing thrombin inhibition.

Keywords

Factor IXa - oligosaccharides - antithrombin - heparin - fondaparinux

^a Thrombosis and Haemostasis

• References

• 1 Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds): Hemostasis and Thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia, PA: JB Lippincott; 1994: 8337-860.
• 2 Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-38.
• 3 Petitou M, Duchaussoy P, Driguez PA, Jaurand G, Hérault JP, Lormeau JC, van Boeckel CAA, Herbert JM. First Synthetic Carbohydrates with the Full Anticoagulant Properties of Heparin. Angew Chem Int Ed Engl 1998; 37: 3009-14.
• 4 Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995; 86: 1794-801.
• 5 Wong AG, Gunn AC, Ku P, Hollenbach SJ, Sinha U. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arteriovenous thrombosis. Thromb Haemost 1997; 77: 1143-7.
• 6 Feuerstein GZ, Patel A, Toomey JR, Bugelski P, Nichols AJ, Church WR, Valocik R, Koster P, Baker A, Blackburn MN. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. Arterioscler Thromb Vasc Biol 1999; 19: 2554-62.
• 7 Holmer E, Kurachi K, Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
• 8 Petitou M, Hérault JP, Bernat A, Driguez P, Duchaussoy P, Lormeau JC, Herbert JM. Synthesis of thrombin inhibiting heparin mimetics without side effects. Nature 1999; 398: 417-22.
• 9 Petitou M, Duchaussoy P, Driguez PA, Hérault JP, Lormeau JC, Herbert JM. New synthetic heparin mimetics able to inhibit thrombin and factor Xa. Bioorg Med Chem Lett 1999; 09: 1155-60.
• 10 Petitou M, Duchaussoy P, Driguez PA, Hérault JP, Lormeau JC, Herbert JM. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics. Bioorg Med Chem Lett 1999; 09: 1161-6.
• 11 Driguez PA, Lerderman I, Strassel JM, Herbert JM, Petitou M. Synthetic carbohydrate derivatives as low sulphated heparin mimetics. J Org Chem 1999; 26: 9512-20.
• 12 Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HM, Zandberg P, van Amsterdam RGM, Van Boeckel CAA, Meuleman DG. SR90107A/Org31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15: 1-26.
• 13 Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001; 344: 619-25.
• 14 Herbert JM, Hérault JP, Bernat A, Savi P, Schaeffer P, Driguez AP, Duchaussoy P, Petitou M. SR123781A, a synthetic heparin mimetic. Thromb Haemost 2001; 85: 852-60.
• 15 Pieters J, Willems G, Hemker C, Lindhout T. Inhibition of factor IXa and factor Xa by antithrombin III/heparin inhibiting factor X activation. J Biol Chem 1988; 263: 15313-8.
• 16 Herbert JM, Hérault JP, Bernat A, van Amsterdam RGM, Lormeau JC, Petitou M, van Boeckel C, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of Sanorg34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 11: 4197-205.
• 17 Petitou M, Imberty A, Duchaussoy P, Driguez PA, Ceccato ML, Gourvenec F, Sizun P, Herault JP, Perez S, Herbert JM. An Experimental Proof for the Structure of a Thrombin-Inhibiting Heparin Molecule. Chem Eur J 2001; 07: 858-73.
• 18 Pieters J, Lindhout T, Willems G. Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralisation in plasma. Blood 1990; 76: 549-54.
• 19 Wiebe E, O’Brien L, Stafford A, Fredenburgh J, Weitz J. Heparin catalysis of factor IXa inhibition by antithrombin: pentasaccharide-induced conformational change in antithrombin predominates over the template effect. Supplement to the journal Thrombosis and Haemostasis. 2001. ISTH; Paris: Abstract P2101..
• 20 Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 10: 10081-90.